Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.

Science signaling - 9 Jun 2015

Fasci Domenico, Anania Veronica G, Lill Jennie R, Salvesen Guy S

Abstract excerpt

Acute promyelocytic leukemia is characterized by a chromosomal translocation that produces an oncogenic fusion protein of the retinoic acid receptor α (RARα) and promyelocytic leukemia protein (PML). Arsenic trioxide chemotherapy of this cancer induces the PML moiety to organize nuclear bodies, where the oncoprotein is degraded. This process requires the participation of two SUMO paralogs (SUMO1 and SUMO2) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals
Share to Cysteine Endopeptidases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oxides

Share to Promyelocytic Leukemia Protein

Share to Small Ubiquitin-Related Modifier Proteins

Share to SUMO-1 Protein

Share to Ubiquitination

Source

Open in PubMed Open full text

Identifiers

PMID: 26060329
DOI: 10.1126/scisignal.aaa3929
PMCID: PMC4603552

Genes

PML
SUMO2
RNF4
SUMO1
SENP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.PMID 26060329Read ↗

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.Semantic proximity Read ↗

Sumoylation in Physiology, Pathology and TherapySemantic proximity Read ↗

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways.Semantic proximity Read ↗

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.Semantic proximity Read ↗

The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.Semantic proximity Read ↗

Sumoylation: a regulatory protein modification in health and disease.Semantic proximity Read ↗

SUMOylation and deSUMOylation at a glanceSemantic proximity Read ↗

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Semantic proximity Read ↗

Therapeutic Potential of Targeting the SUMO Pathway in CancerSemantic proximity Read ↗

The post-translational modification, SUMOylation, and cancer (Review)Semantic proximity Read ↗

Acute promyelocytic leukemia, arsenic, and PML bodiesSemantic proximity Read ↗

PML mutants resistant to arsenic induced degradation fail to generate the appropriate SUMO and ubiquitin signals required for RNF4 and p97 recruitmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.